Director-level immunologist.
Bridging bench science
to clinical programs.
Over a decade of drug discovery experience spanning innate immune signaling, immuno-oncology, and age-related disease. Built and led research teams at Aduro Biotech, Tizona Therapeutics, RAPT Therapeutics, and Deciduous Therapeutics — connecting rigorous preclinical science with translational program strategy.
Known for exceptional flow cytometry expertise, high-dimensional data analysis, and mentoring scientists at every career stage. Currently consulting and building computational tools for immunology programs.
Immunology Program Support
My experience spans both ends — early mechanistic research through Phase I — so I understand how the science needs to translate as programs mature. Most useful as a scientific sounding board or to help scope immunology workstreams: thinking through immunology strategy, preclinical-to-clinical translation, biomarker frameworks for early clinical studies, or helping a small team build out its immunology function. Also happy to assist with CRO scoping or academic collaboration.
- Thinking through immunology strategy for a program
- Preclinical-to-clinical translation planning
- Helping a small team build out its immunology work
- Input on biomarker frameworks for early clinical studies
- CRO scoping & academic collaboration support
Flow Cytometry Support
Flow cytometry is probably where I can be most immediately useful. I've spent a lot of time on panel design, gating, and making cytometry data actually tell a story — happy to help troubleshoot, review a panel, or think through an analysis approach.
- Panel design review & optimization suggestions
- Gating strategy feedback
- Platform selection guidance (spectral vs. conventional)
- Assay design for primary immune cells
- Informal training or working through analysis together
Data Analysis & Bioinformatics
I'm comfortable in R and FlowJo, and have done clinical biomarker analysis in Phase I settings. Not a dedicated bioinformatician, but I can help bridge the gap between wet lab data and what you need to show scientifically.
- High-dimensional cytometry analysis (FlowJo, R)
- Biomarker readout planning for early clinical studies
- Helping make sense of immune datasets
Translational Input
Having worked on programs that went from mouse models into Phase I, I understand what questions come up as you move toward the clinic. I can help think through how to use preclinical data to build a translational story, and what to measure in early patients.
- Connecting preclinical findings to clinical hypotheses
- Proof-of-mechanism study design
- Immunophenotyping of clinical samples
- Combination strategy thinking (e.g., checkpoint + agonist)
- Scientific advisory conversations
Intelligent Gating Tool
AI-enabled gating assistance for flow cytometry analysis. Define hierarchical gating strategies, annotate populations, and generate reproducible gating reports — without the tedium.
- Define hierarchical gating strategies and annotate populations with reproducible gating reports
- Export-ready gating trees with metadata annotations
- Supports common immune phenotyping panels (T cell, NK, DC, myeloid)
Immune Panel Builder
Smart spectral unmixing and panel design for multicolor flow cytometry. Avoid fluorochrome conflicts and optimize reagent combinations for your laser configuration.
- Avoid fluorochrome conflicts and optimize reagent combinations for your laser config
- Fluorochrome compatibility checker across common cytometer configs
- Clone and antibody suggestions ranked by literature usage
At Aduro Biotech, I was a core contributor to the STING agonist program, helping develop ADU-S100 (MIW815) from mechanistic research through Phase I clinical trial design — including dose selection and interpretation of clinical results. At Tizona Therapeutics, I led the translational team that developed Phase I PD markers for a lead clinical asset, and managed a new targets project identifying and validating novel immunology ideas.
Most recently, as Director of Immunology at Deciduous Therapeutics, I built the immunology function from the ground up, advancing redosable iNKT-based drug candidates and leading the team through high-complexity in vitro and in vivo programs. Across these roles I've been known for exceptional flow cytometry expertise — panel design, high-throughput data analysis, and implementing new analytical platforms — and for mentoring scientists at every career stage.
Tony's work was instrumental in our understanding of ADU-S100. His ability to bridge the gap between preclinical findings and clinical observations was a tremendous asset, helping us make informed decisions about the development of the ADU-S100 program.
Tony expertly built our immunology function from the ground up under challenging circumstances. His leadership in advancing our therapeutic programs, particularly the development of redosable iNKT-based drug candidates — a significant hurdle in the field — was remarkable.
Tony also has exceptional expertise in flow cytometry, particularly in panel design, evaluation, and optimization, and high-throughput data analysis. His critical eye and thoughtful guidance elevated the skills of researchers at every level.
I was particularly impressed with his ability to analyze large data sets with exceptional rigor to generate clear and significant results. He brings a sense of dry wit and humor to his leadership style and is an advocate for continued growth and learning for his team.